Live Webinar: The Ultimate Cleaning Validation Audit Readiness Blueprint. Register Now
Live Webinar: The Ultimate Cleaning Validation Audit Readiness Blueprint. Register Now
Experience Leucine AI .
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System /
Stability Studies
Stability Studies
View Detailed Analysis

Analytics Overview

50
Form 483s Issued
13
483s converted to WL
58
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
11 Jul 2025
Center for Drug Evaluation and Research
Drugs
27 Jun 2025
BSO, LLC
Drugs
13 Jun 2025
Sun Pharmaceutical Industries Ltd.
Drugs
23 May 2025
Stokes Healthcare Inc. dba Epicur Pharma
Drugs
10 Apr 2025
Aurolige Pharma LLC
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Justin A Boyd
7
6
Anastasia M Shields
4
4
Crystal Monroy
4
2
Arsen Karapetyan
3
1
Edmund F Mrak
3
1
TITLE/ COMPANY Issue Date Status Details
Your firm failed to establish an adequate written testing program to assess the stability characteristics of drug products.
Center for Drug Evaluation and Research
11 Jul 2025 Normal Justification: Stability Studies process type is directly linked to the issue as the oversight occurred in the execution of stability testing protocols.
Excerpt: The stability studies conducted for Hydrocodone Bitartrate and Acetaminophen Tablets USP 10 mg/325 mg did not include testing for dissolution.
View Details
The written stability program for drug products does not include specific test methods.
BSO, LLC
27 Jun 2025 Normal Justification: Stability studies ensure drug products maintain quality over time. Missing tests (photostability, dissolution, impurities) affect this process.
Excerpt: Stability Study BSO.SS.001 does not contain any data to demonstrate that the packaging protects the drug from photodegradation.
View Details
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
Sun Pharmaceutical Industries Ltd.
13 Jun 2025 Normal Justification: Failure in monitoring and responding to stability data trends directly affects the integrity of stability studies.
Excerpt: Your Quality Unit did not investigate out of trend test results of an annual stability batch...
View Details
There is no written testing program designed to assess the stability characteristics of drug products.
Stokes Healthcare Inc. dba Epicur Pharma
23 May 2025 Normal Justification: The observation highlights a deficiency in the stability study, specifically related to impurity testing, a core component of Stability Studies.
Excerpt: Stability study failed to test for impurities of Tacrolimus Ophthalmic Suspension including (b) (4) individual unspecified impurities.
View Details
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications
Aurolige Pharma LLC
10 Apr 2025 Normal Justification: Stability Studies processes were compromised due to inappropriate acceptance of sample results and unidentified peaks in analyses.
Excerpt: During the review of analytical raw data mg Lot assay determination I observed an unidentified peak.
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.

Stability Studies

Explore essential insights on batch release processes to enhance compliance and quality. Dive into our article for practical guidance and best practices.

Written By
Vivek Gera
Reading Time
8
Minutes

Stability Studies

Overview

50
Form 483s Issued
13
483s converted to WL
58
Total Observation
Form 483s Issued
+74 from last period

Recent Form 483s & Warning Letters

Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
11 Jul 2025
Center for Drug Evaluation and Research
Drugs
27 Jun 2025
BSO, LLC
Drugs
13 Jun 2025
Sun Pharmaceutical Industries Ltd.
Drugs
23 May 2025
Stokes Healthcare Inc. dba Epicur Pharma
Drugs
10 Apr 2025
Aurolige Pharma LLC
Drugs

Top FDA Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Justin A Boyd
7
6
Anastasia M Shields
4
4
Crystal Monroy
4
2
Arsen Karapetyan
3
1
Edmund F Mrak
3
1

Key Observations

TITLE/ COMPANY Issue Date Status Details
Your firm failed to establish an adequate written testing program to assess the stability characteristics of drug products.
Center for Drug Evaluation and Research
11 Jul 2025 Normal Justification: Stability Studies process type is directly linked to the issue as the oversight occurred in the execution of stability testing protocols.
Excerpt: The stability studies conducted for Hydrocodone Bitartrate and Acetaminophen Tablets USP 10 mg/325 mg did not include testing for dissolution.
View Details
The written stability program for drug products does not include specific test methods.
BSO, LLC
27 Jun 2025 Normal Justification: Stability studies ensure drug products maintain quality over time. Missing tests (photostability, dissolution, impurities) affect this process.
Excerpt: Stability Study BSO.SS.001 does not contain any data to demonstrate that the packaging protects the drug from photodegradation.
View Details
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
Sun Pharmaceutical Industries Ltd.
13 Jun 2025 Normal Justification: Failure in monitoring and responding to stability data trends directly affects the integrity of stability studies.
Excerpt: Your Quality Unit did not investigate out of trend test results of an annual stability batch...
View Details
There is no written testing program designed to assess the stability characteristics of drug products.
Stokes Healthcare Inc. dba Epicur Pharma
23 May 2025 Normal Justification: The observation highlights a deficiency in the stability study, specifically related to impurity testing, a core component of Stability Studies.
Excerpt: Stability study failed to test for impurities of Tacrolimus Ophthalmic Suspension including (b) (4) individual unspecified impurities.
View Details
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications
Aurolige Pharma LLC
10 Apr 2025 Normal Justification: Stability Studies processes were compromised due to inappropriate acceptance of sample results and unidentified peaks in analyses.
Excerpt: During the review of analytical raw data mg Lot assay determination I observed an unidentified peak.
View Details

Frequently Asked Questions

Heading 1

Heading 2

Heading 3

Heading 4

Heading 5
Heading 6

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Block quote

Ordered list

  1. Item 1
  2. Item 2
  3. Item 3

Unordered list

  • Item A
  • Item B
  • Item C

Text link

Bold text

Emphasis

Superscript

Subscript

Experience Leucine AI Powered pharma manufacturing
300+ pharma facilities worldwide use Leucine to stay compliant. Talk to one of our expert consultants at Leucine to learn how.
Related Resources

View and learn more about FDA Inspections
with our comprehensive list of resources